Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data

Meir Schechter; Cheli Melzer Cohen; Tamir Zelter; Ilan Yanuv; Aliza Rozenberg; Gabriel Chodick; Avraham Karasik; Ofri Mosenzon

doi:10.1111/dom.15172

Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data

Meir Schechter, Cheli Melzer Cohen, Tamir Zelter, Ilan Yanuv, Aliza Rozenberg, Gabriel Chodick, Avraham Karasik, Ofri Mosenzon^*

^*Corresponding author for this work

Faculty of Medical Sciences/UMCG

Research output: Contribution to journal › Letter › Academic › peer-review

2 Downloads (Pure)

Original language	English
Pages (from-to)	3054-3058
Number of pages	5
Journal	Diabetes, Obesity and Metabolism
Volume	25
Issue number	10
DOIs	https://doi.org/10.1111/dom.15172
Publication status	Published - Oct-2023

Access to Document

10.1111/dom.15172Licence: CC BY-NC

Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world dataFinal publisher's version, 753 KBLicence: CC BY-NC

Handle.net

Persistent link

Cite this

Schechter, M., Melzer Cohen, C., Zelter, T., Yanuv, I., Rozenberg, A., Chodick, G., Karasik, A., & Mosenzon, O. (2023). Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data. Diabetes, Obesity and Metabolism, 25(10), 3054-3058. https://doi.org/10.1111/dom.15172

@article{b2e1113805ed46b48891d9afbb6781d1,

title = "Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data",

author = "Meir Schechter and {Melzer Cohen}, Cheli and Tamir Zelter and Ilan Yanuv and Aliza Rozenberg and Gabriel Chodick and Avraham Karasik and Ofri Mosenzon",

note = "Funding Information: This was an investigator‐initiated project. The study was funded by Boehringer Ingelheim. The funder was involved in study design by means of providing nonbinding scientific expert advice and approved this report. This report was written by the investigators and the decision to submit for publication was made solely by the investigators. ",

year = "2023",

month = oct,

doi = "10.1111/dom.15172",

language = "English",

volume = "25",

pages = "3054--3058",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley",

number = "10",

}

Schechter, M, Melzer Cohen, C, Zelter, T, Yanuv, I, Rozenberg, A, Chodick, G, Karasik, A & Mosenzon, O 2023, 'Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data', Diabetes, Obesity and Metabolism, vol. 25, no. 10, pp. 3054-3058. https://doi.org/10.1111/dom.15172

Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data. / Schechter, Meir; Melzer Cohen, Cheli; Zelter, Tamir et al.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 10, 10.2023, p. 3054-3058.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease

T2 - Real-world data

AU - Schechter, Meir

AU - Melzer Cohen, Cheli

AU - Zelter, Tamir

AU - Yanuv, Ilan

AU - Rozenberg, Aliza

AU - Chodick, Gabriel

AU - Karasik, Avraham

AU - Mosenzon, Ofri

N1 - Funding Information: This was an investigator‐initiated project. The study was funded by Boehringer Ingelheim. The funder was involved in study design by means of providing nonbinding scientific expert advice and approved this report. This report was written by the investigators and the decision to submit for publication was made solely by the investigators.

PY - 2023/10

Y1 - 2023/10

U2 - 10.1111/dom.15172

DO - 10.1111/dom.15172

M3 - Letter

C2 - 37385956

AN - SCOPUS:85164185328

SN - 1462-8902

VL - 25

SP - 3054

EP - 3058

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 10

ER -